awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2B
Q38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2B
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
P2860
Q38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38521011-0F8E3479-BEA9-4C25-AD84-3AE70E412F2B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bc34d16d14d7fde6f1663ca633cb568559e98a05
P2860
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.